About Orphan Reach
Orphan Reach is a Healthcare company based in Milton Keynes (United Kingdom) founded in 2012, and was acquired by Emmes in May 2021. Rare diseases and orphan drugs development services are specialized in. Orphan Reach offers products and services including Biostatistics Services, Clinical Data Management, Clinical Trial Management, Pharmacovigilance Services, and Endpoint Solutions. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Full Service. Its legal entity is The Emmes Company, LLC.
Company details
Orphan Reach is a CRO focussed on rare diseases and orphan drugs development. They offer early development services (regulatory strategy planning, orphan drug designation, FDA and EMA Meeting Preparation and Representation etc.,), natural history studies (studies that follow a group of people over time who have or are at risk of developing a specific disease), clinical trial management solutions (project management, biostatistics, regulatory affairs etc.,), patient home support and post marketing surveillance services. They claim to have special focus on patient recruitment and retention for orphan drug trials. They also offer their services for pediatric drugs and rare diseases. They claim to have access to patients with rare diseases in more than 100 countries world-wide.
- Headquarters Milton Keynes, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website orphan-reach.com
- Social LinkedIn X
- Acquired by Emmes (May 2021)
- Legal Name The Emmes Company, Llc
Products & Services of Orphan Reach
Orphan Reach offers a comprehensive portfolio of products and services, including Biostatistics Services, Clinical Data Management, Clinical Trial Management, Pharmacovigilance Services, and Endpoint Solutions.
Statistical support for clinical trial design and analysis
Management of data in clinical research studies
Oversight of trial execution and regulatory affairs
Monitoring and reporting of adverse events in trials
Tools for assessing trial endpoints and patient outcomes
Investors in Orphan Reach
Orphan Reach has secured backing from 1 investor. Prominent investors backing the company include Emmes.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Outsourced contract research organization services are provided to clients. | 1977 | emmes.com | United States |
Investor details for Orphan Reach
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Orphan Reach
2 dated milestones of Orphan Reach across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Orphan Reach is founded.
- Exit Acquired by Emmes.
Web traffic of Orphan Reach
The website of Orphan Reach (orphan-reach.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 5.6% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Orphan Reach
Complete news archive for Orphan Reach
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orphan Reach
Orphan Reach was founded in 2012.
Orphan Reach is headquartered in Milton Keynes, United Kingdom.
Orphan Reach is a CRO focussed on rare diseases and orphan drugs development. They offer early development services (regulatory strategy planning, orphan drug designation, FDA and EMA Meeting Preparation and Representation etc.,), natural history studies (studies that follow a group of people over time who have or are at risk of developing a specific disease), clinical trial management solutions (project management, biostatistics, regulatory affairs etc.,), patient home support and post marketing surveillance services. They claim to have special focus on patient recruitment and retention for orphan drug trials. They also offer their services for pediatric drugs and rare diseases. They claim to have access to patients with rare diseases in more than 100 countries world-wide.
Orphan Reach offers Biostatistics Services, Clinical Data Management, Clinical Trial Management, Pharmacovigilance Services, and Endpoint Solutions.
Orphan Reach has 1 investor. Key investors include Emmes.
Orphan Reach operates through The Emmes Company, Llc.
Yes. Orphan Reach was acquired by Emmes in May 2021.